Clinical Study
Effectiveness of Acupuncture Treatment on Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized, Assessor-Blinded, Controlled Trial
Table 1
Comparison of participants’ baseline demographic and clinical characteristics between two groups.
| Characteristics | Acupuncture (N = 19) | Vit B1 and gabapentin (N = 19) | value |
| Age, mean ± SD, years | 57.95 (10.39) | 58.79 (8.36) | 0.79 | Gender, no. (%) | | | 0.74 | Male | 7 (36.8) | 8 (42.1) | | Female | 12 (63.2) | 11 (57.9) | | Cancer type, no. (%) | | | 0.91 | Breast cancer | 10 (52.6) | 8 (42.1) | | Lung cancer | 1 (5.3) | 0 | | Ovarian cancer | 0 | 1 (5.3) | | Prostate cancer | 1 (5.3) | 1 (5.3) | | Colorectal cancer | | | | Colon | 3 (15.8) | 5 (26.3) | | Rectum | 4 (21.1) | 4 (21.1) | | Chemotherapy agents, no. (%) | | | 0.93 | Taxane | 1 (5.3) | 1 (5.3) | | Platinum compound | 7 (36.8) | 9 (47.4) | | Platinum compound-taxane | 1 (5.3) | 1 (5.3) | | Doxorubicin/cyclophosphamide-taxane | 10 (52.6) | 8 (42.1) | | Duration of neuropathy, mean ± SD, month | 7.16 (7.06) | 7.47 (5.32) | 0.88 | Number of chemotherapy courses, mean ± SD | 7.58 (2.63) | 7.42 (1.98) | 0.84 | Patients symptoms, no. (%) | | | | Pain | | | 0.72 | Yes | 14 (73.7) | 13 (68.4) | | No | 5 (26.3) | 6 (31.6) | | Numbness | | | | Yes | 18 (94.7) | 18 (94.7) | | No | 1 (5.3) | 1 (5.3) | | Paresthesia | | | | Yes | 19 (100) | 19 (100) | | No | 0 | 0 | | Subjective impairment in walking | | | 0.63 | Yes | 3 (15.8) | 2 (10.5) | | No | 16 (84.2) | 17 (89.5) | |
|
|
values from between-group comparison using the independent samples test. values from between-group comparisons using the chi-square test. |